Tavira Therapeutics
0802.591.262 · rovalta.com · 25/09/2026
Tavira Therapeutics
Financial year 2025 · Closed on 31/12/2025
Overview
Identity
Source · BCE/KBOTavira Therapeutics is a Private limited company incorporated in 2023. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Leuven.
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0802.591.262
- Incorporation
- 09/06/2023
- Legal form
- Private limited company
- Registered office
- Gaston Geenslaan 3
3001 Leuven · FlandreSee on map - Contributed capital
- 1 415 817,61 €
- Latest accounts
- 31/12/2025
Joint committees (1)
- 200
Financials
Source · NBB, 3 filingsTrend over 2 financial years
| 2025 | 2024 | ||
|---|---|---|---|
| Income statement | |||
| Gross margin | 308,6 k € | +353% | -122,1 k € |
| EBITDA | 173,1 k € | +221% | -143,4 k € |
| Operating result | -540,4 k € | +42.6% | -941,2 k € |
| Net result | -567,7 k € | +38.3% | -920,7 k € |
| Balance sheet | |||
| Equity | -72,5 k € | -130% | 245,1 k € |
| Total assets | 863,7 k € | -22.4% | 1,1 M € |
| Cash | 170,2 k € | -47.8% | 326 k € |
| Debts | 927,2 k € | +6.8% | 868,4 k € |
Valuation
Indicative valuation
As an indication, this company is worth
Board of directors
Source · NBB, accounts to 31/12/20255 active
Active mandates
Other companies at this address
Gaston Geenslaan 3 3001 Leuven| Company | CBE no. |
|---|---|
AstriVax Therapeutics● Active | 0787.990.881 |
AUGUSTINE THERAPEUTICS● Active | 0722.705.230 |
COULTREON BIOPHARMA● Active | 1019.429.814 |
K5 Therapeutics● Active | 0757.718.072 |
Metaptys● Active | 0554.664.311 |
Montis Biosciences● Active | 0730.979.429 |
Perseus Biomics● Active | 0650.946.412 |
QUOMAK● Active | 0448.488.111 |
ReWind Therapeutics● Active | 0682.626.216 |
| 1040.853.946 | |
VEDRA THERAPEUTICS● Active | 1039.565.628 |
Financials
Full financial information
Source · NBB| 2025 | 2024 | |
|---|---|---|
| Type of account | Micro model | Micro model |
| Start of the financial year | 01/01/2025 | 09/06/2023 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 |
| Length of the financial year | 12 months | 19 months |
| Filing date | 03/07/2026 | 17/07/2025 |
| General meeting | 30/06/2026 | 15/05/2025 |
| Currency of the financial year | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for 7 daysAnnual accounts filings
Source · NBB, 3 filingsValuation
Indicative valuation
As an indication, this company is worth
between 0 € and 100 k€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20255 active
Active mandates
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette publications
Source · Belgian Official Gazette- Capital / shares05/11/2025KAPITAAL - AANDELEN
- Mandates25/04/2025ONTSLAGEN - BENOEMINGEN
- Registered office25/11/2024MAATSCHAPPELIJKE ZETEL
- Mandates11/04/2024DIVERSEN - KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN
- Mandates20/06/2023KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN
- Other13/06/2023RUBRIEK OPRICHTING (NIEUWE RECHTSPERSOON, OPENING BIJKANTOOR, ENZ...)
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025-567,7 k €↑
- 2024Annual accounts 2024-920,7 k €
- 09/06/2023IncorporationPrivate limited company